Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Upgraded by StockNews.com
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating ...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by M&T Bank Corp
M&T Bank Corp lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 23.4% in the fourth ...
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing ...
Le Lézard5d
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum
Neurocrine Biosciences, Inc. will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief Executive Officer Kyle Gano and Chief Medical Officer ...
Neurocrine price target lowered to $139 from $148 at RBC Capital
RBC Capital lowered the firm’s price target on Neurocrine (NBIX) to $139 from $148 and keeps a Sector Perform rating on the shares. The payer ...